Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Price: 143 GBX -11.73% Market Closed
Market Cap: 457.1m GBX

Gross Margin
Amryt Pharma Holdings Ltd

49.2%
Current
41.4%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
49.2%
=
Gross Profit
103.4m
/
Revenue
210.2m

Gross Margin Across Competitors

No Stocks Found

Amryt Pharma Holdings Ltd
Glance View

Market Cap
453.2m GBX
Industry
Pharmaceuticals

Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The firm is focused on developing and commercialization of treatments for orphan and rare diseases patients. The Company’s commercial business provides orphan disease products, which includes Juxtapid/ Lojuxta and Myalept / Myalepta. The Company’s lead development candidate is FILSUVEZ.

AMYT Intrinsic Value
Not Available
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
49.2%
=
Gross Profit
103.4m
/
Revenue
210.2m
What is the Gross Margin of Amryt Pharma Holdings Ltd?

Based on Amryt Pharma Holdings Ltd's most recent financial statements, the company has Gross Margin of 49.2%.

Back to Top